Venus_Remedies gets Saudi_FDA Plerixafor approval
Analysis based on 8 articles · First reported May 22, 2026 · Last updated May 23, 2026
The approval of Plerixafor>>> by the Saudi Arabia — Saudi Food and Drug Authority>>> for Tridus Remedies>>> is expected to positively impact Tridus Remedies>>>'s stock price due to expanded market access and a strengthened specialty oncology portfolio. It also signals growth in the Saudi Arabia>>>n pharmaceutical market, potentially attracting further investment in the healthcare sector.
Tridus Remedies>>> has received its first global marketing authorization from the Saudi Arabia — Saudi Food and Drug Authority>>> for Plerixafor>>>, a specialty oncology therapy. This approval allows Tridus Remedies>>> to commercialize Plerixafor>>> 24mg/1.2ml in Saudi Arabia>>> through its international business network, targeting tertiary oncology and transplant centers. Plerixafor>>> is a stem cell mobilization therapy used in conjunction with G-CSF for autologous transplantation in patients with multiple myeloma and non-Hodgkin lymphoma. This move is part of Tridus Remedies>>>'s strategy to expand into complex specialty injectables and reduce reliance on high-volume commodity products. Bhupesh Chaudhary>>> and Aditi K. Chaudhary>>> of Tridus Remedies>>> highlighted Saudi Arabia>>> as a strategic launch market due to its growing pharmaceutical market, projected to reach USD 17.1 billion by 2033, and increasing demand for stem cell therapies in the Gulf Cooperation Council>>> region.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard